Product Program year 2023 Source: CMS Open Payments

Iluvien

Drug Ophthalmology

NDC 68611-190-02

Open in the dashboard

General payments

$2,470,392

12,924 payments

Research payments

$122,860

38 payments

Through program year 2023, $2,470,392 in general payments and $122,860 in research payments were reported against Iluvien (Ophthalmology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

8 rows
Year Kind Amount Payments
2023 General $525,931 2,743
2022 General $656,591 3,264
2022 Research $52,433 9
2021 General $401,590 2,406
2020 General $221,465 1,529
2020 Research $8,643 1
2019 General $664,814 2,982
2019 Research $61,784 28

Breakdown

Who paid General payments · program years 2019–2023
  1. Alimera Sciences, Inc. $2,470,392 12,924 payments
Top recipients General payments · program year 2023
  1. Jorge Fortun Ophthalmology · Palm Beach Gardens, FL $25,888 5% · 14 payments
  2. Michael Singer Ophthalmology · San Antonio, TX $21,887 4% · 11 payments
  3. Lisa Faia Retina Specialist · Royal Oak, MI $21,657 4% · 12 payments
  4. Dilsher Dhoot Retina Specialist · Santa Barbara, CA $21,592 4% · 11 payments
  5. Donald Mazzulla Retina Specialist · New Orleans, LA $19,102 4% · 20 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2023.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2023
  1. Ophthalmology $268,460 51% · 672 practitioners
  2. Retina Specialist Ophthalmology $246,181 47% · 412 practitioners
  3. Uveitis and Ocular Inflammatory Disease Ophthalmology $8,716 2% · 14 practitioners
  4. Optometrist $1,609 <1% · 47 practitioners
  5. Hospitalist $297 <1% · 1 practitioner

The top 5 of 12 specialties; each share is of general payments naming this product to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2023
  1. Florida $79,138 15% · 90 recipients
  2. Michigan $60,465 11% · 45 recipients
  3. Texas $57,431 11% · 95 recipients
  4. California $53,064 10% · 122 recipients
  5. Ohio $45,312 9% · 79 recipients

The top 5 of 47 states; each share is of general payments naming this product in 2023 where a state was reported.

The top 25 states, free in the app

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to ILUVIEN
Billing code Providers Services Paid by Medicare
Injection, fluocinolone acetonide, intravitreal implant, 0.01 mg J7313 5 1,787 $680,143

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

12,924 general · 38 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record